- This event is over. However, time travel possible through our Audio & Video!
Earlier this month, Dr. Katalin Karikó and Dr. Drew Weissman were jointly awarded the Nobel Prize for their groundbreaking work which led to the development of mRNA vaccines. Demystifying Vaccines is an opportunity to delve into India’s journey of creating mRNA vaccines for COVID-19 and explore potential future applications of mRNA technology in vaccines and therapeutics.
From tracing the history of mRNA-based platforms in vaccinology to challenges and opportunities presented by technology, this session will explore the future of this rapidly changing landscape.
The program starts with a talk on the development of mRNA vaccines for COVID-19 in India, followed by a popular science talk on RNA biology and a panel discussion on the potential of the mRNA technology in vaccinology.
In collaboration with:
Dr. Sanjay Singh is the Founder and Chief Executive Officer of Gennova Biopharmaceuticals Ltd, Pune, India, a biotechnology company dedicated to the development and commercialization of safe, efficacious, and affordable bio-therapeutics.
Arati Ramesh is currently a Principal Scientist at the Tata Institute for Genetics and Society, and was formerly faculty at the National Center for Biological Sciences, Bangalore. She received her Ph.D from Texas A&M University, College Station and pursued her post-doctoral research at the University of Texas Southwestern Medical Center, Dallas. Her research group explores the biology of RNA in micro-organisms, how RNA sensors help microbes sense their environment and the role these RNAs play in
making microbes resistant to antibiotics.
She is a virologist/molecular biologist with an interest in viruses – particularly those that are novel, emerging and/or cause human disease.
Rajesh V Iyer
V. Rajesh Iyer is a research scientist working on the development of mRNA biotherapeutic platform for rare genetic disorders and cancer at Tata Institute for Genetics and Society (TIGS). Earlier, at Centre for Cellular and Molecular Biology, he worked as a project scientist in CSIR sanctioned mission-mode project on mRNA platforms for vaccine and biologics and played a vital role in the development of a potential mRNA vaccine candidate for COVID-19, that has shown promising results in the preclinical trials conducted in mice and hamsters. He did his Ph.D. from CCMB on elucidating the peculiarities of mismatch repair pathway on the mutation rates and cell biology of E.coli. He did his master’s in biotechnology from IIT-Roorkee, where he was involved in the design and development of synthetic inducible promoter sequences and their mechanism of regulation. His research experience is primarily in the field of mRNA technology, molecular biology, genetics, microbiology, and synthetic biology.
Dr. Swetha Raghavan holds a Ph.D. from IIT Madras and post-doctoral experience as part of Dr. Sudhir Krishna’s group at National Centre for Biological Sciences (NCBS-TIFR). Her primary interests revolve around unravelling the fundamental mechanisms that could contribute to the development of disease interventions. Presently, she is a Project Scientist in the Dengue Vaccine Program (funded by Shri Narayana Murthy), concentrating on the creation of mRNA-based vaccines targeting Dengue. Additionally, she is a recipient of the Biotech Ignition Grant and is currently incubated at CCAMP in Bangalore.
Monalisa Chatterji has over 20 years of experience, both in small molecules and biologics discovery and development. She received an Integrated M.S. & Ph.D. from Indian Institute of Science and carried out postdoctoral research at Yale University, USA. During her career, Dr. Chatterji has led diverse functional domains and programs in multiple organization namely, AstraZeneca, Biocon, Kinexum and Bill & Melinda Gates Foundation. She has also served in different consortia and accelerators focused on drug discovery – MM4TB, CARE, TBDA, ACT etc. She is the innovator for TBA-7371 (anti-infective), and T1h (Mab) at AstraZeneca, and Biocon respectively.
She is the recipient of Young Scientist award, NASI, Govt of India for her graduate research. In 2022, she was recognised among 75 women by the PSA office, Government of India for “excellence in the fields of STEAM (fields of Science, Technology, Engineering, Arts and Mathematics)”. Dr. Chatterji is the co-founder of Sekkei Bio Pvt ltd in India. Sekkei Bio’s
mission is to develop cutting edge technologies & novel therapeutics addressing global critical unmet needs.